FDA requests more data on AstraZeneca diabetes treatment

AstraZeneca said the U.S. Food and Drug Administration (FDA) issued a complete response letter (CRL) about the new drug application (NDA) for the investigational fixed-dose combination of saxagliptin and dapagliflozin. The fixed-dose combination of saxagliptin and dapagliflozi is intended for the treatment of adult patients with Type 2 diabetes.  The CRL said more clinical data is required to support NDA. Read More »

FDA grants accelerated approval for Keytruda for lung cancer treatment

The U.S. Food and Drug Administration (FDA) granted accelerated approval on Friday for Keytruda (pembrolizumab) to treat patients with advanced (metastatic) non-small cell lung cancer (NSCLC) whose disease has progressed after other treatments and with tumors that express a protein called PD-L1. Keytruda, marketed by Merck, works by targeting the cellular pathway known as PD-1/PD-L1, which are proteins found on the body’s immune cells and some cancer cells. Through blocking this pathway, Keytr Read More »